300519 新光药业
交易中 06-05 14:35:27
资讯
新帖
简况
新光药业（300519）披露2025年年度权益分派实施公告，5月21日股价下跌3.47%
证券之星 · 05-21
新光药业（300519）披露2025年年度权益分派实施公告，5月21日股价下跌3.47%
新光药业（300519）披露2025年年度股东会决议公告，5月18日股价上涨0.82%
证券之星 · 05-18
新光药业（300519）披露2025年年度股东会决议公告，5月18日股价上涨0.82%
新光药业(300519)3月31日股东户数1.49万户，较上期减少0.68%
证券之星 · 04-21
新光药业(300519)3月31日股东户数1.49万户，较上期减少0.68%
新光药业(300519.SZ)发布一季度业绩，归母净利润2636.8万元，增长7.44%
智通财经 · 04-20
新光药业(300519.SZ)发布一季度业绩，归母净利润2636.8万元，增长7.44%
新光药业（300519）披露持股5%以上股东股份减持计划届满公告，3月2日股价下跌4.12%
证券之星 · 03-02
新光药业（300519）披露持股5%以上股东股份减持计划届满公告，3月2日股价下跌4.12%
2月6日新光药业发布公告，股东减持118.11万股
证券之星 · 02-06
2月6日新光药业发布公告，股东减持118.11万股
股市必读：新光药业（300519）1月20日董秘有最新回复
证券之星 · 01-21
股市必读：新光药业（300519）1月20日董秘有最新回复
1月5日新光药业现1笔折价22.24%的大宗交易 合计成交250.32万元
证券之星 · 01-05
1月5日新光药业现1笔折价22.24%的大宗交易 合计成交250.32万元
新光药业：新药“YHTKL”进入工艺及质量标准研究阶段
证券之星 · 2025-12-11
新光药业：新药“YHTKL”进入工艺及质量标准研究阶段
新光药业：产品无外销不包括境外地区
证券之星 · 2025-12-05
新光药业：产品无外销不包括境外地区
新光药业收盘下跌1.54%，滚动市盈率49.32倍，总市值21.42亿元
金融界 · 2025-02-25
新光药业收盘下跌1.54%，滚动市盈率49.32倍，总市值21.42亿元
1月8日新光药业发布公告，其股东减持144.6万股
证券之星 · 2025-01-08
1月8日新光药业发布公告，其股东减持144.6万股
新光药业（300519）1月7日主力资金净卖出405.80万元
证券之星 · 2025-01-07
新光药业（300519）1月7日主力资金净卖出405.80万元
新光药业1月6日现5笔大宗交易 成交金额1194.81万元
新浪证券-红岸工作室 · 2025-01-06
新光药业1月6日现5笔大宗交易 成交金额1194.81万元
1月6日新光药业现5笔折价24.43%的大宗交易 合计成交1194.81万元
证券之星 · 2025-01-06
1月6日新光药业现5笔折价24.43%的大宗交易 合计成交1194.81万元
12月24日新光药业现1笔折价20.8%的大宗交易 合计成交276万元
证券之星 · 2024-12-24
12月24日新光药业现1笔折价20.8%的大宗交易 合计成交276万元
新光药业12月24日现1笔大宗交易 成交金额276万元
新浪证券-红岸工作室 · 2024-12-24
新光药业12月24日现1笔大宗交易 成交金额276万元
新光药业(300519.SZ)股东和丰投资拟减持不超2%股份
智通财经 · 2024-11-29
新光药业(300519.SZ)股东和丰投资拟减持不超2%股份
新光药业（300519）2024年三季报简析：增收不增利
证券之星 · 2024-10-25
新光药业（300519）2024年三季报简析：增收不增利
图解新光药业三季报：第三季度单季净利润同比减39.11%
证券之星 · 2024-10-23
图解新光药业三季报：第三季度单季净利润同比减39.11%
加载更多
公司概况
公司名称：
浙江新光药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-06-24
主营业务：
浙江新光药业股份有限公司的主营业务是中成药、化学药、保健食品的研发、生产和销售。公司的主要产品是黄芪生脉饮、伸筋丹胶囊、西洋参口服液、黄芪生脉颗粒、增液颗粒、慢支固本颗粒、金胆片、玉屏风口服液、参术儿康糖浆、肾石通颗粒、铁皮枫斗颗粒、复方大青叶合剂、胃炎宁颗粒、生脉饮、复方丹参片、清热解毒口服液。
发行价格：
12.20
{"stockData":{"symbol":"300519","market":"SZ","secType":"STK","nameCN":"新光药业","latestPrice":13.4,"timestamp":1780641327000,"preClose":13.25,"halted":0,"volume":1825316,"delay":0,"changeRate":0.0113,"floatShares":113999999,"shares":160000000,"eps":0.3503,"marketStatus":"交易中","change":0.15,"latestTime":"06-05 14:35:27","open":13.29,"high":13.65,"low":13.16,"amount":24468000,"amplitude":0.037,"askPrice":13.44,"askSize":30,"bidPrice":13.4,"bidSize":152,"shortable":0,"etf":0,"ttmEps":0.3503,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780642800000},"marketStatusCode":2,"adr":0,"adjPreClose":13.25,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":14.58,"lowLimit":11.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":160000000,"isCdr":false,"pbRate":2.45,"roa":"--","peRate":38.252926,"roe":"3.1%","epsLYR":0.34,"committee":0.436123,"marketValue":2144000000,"turnoverRate":0.016,"status":0,"floatMarketCap":1529000000},"requestUrl":"/m/hq/s/300519/","defaultTab":"news","newsList":[{"id":"2637337412","title":"新光药业（300519）披露2025年年度权益分派实施公告，5月21日股价下跌3.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337412","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637337412?lang=zh_cn&edition=full","pubTime":"2026-05-21 23:00","pubTimestamp":1779375647,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，新光药业报收于15.01元，较前一交易日下跌3.47%，最新总市值为24.02亿元。该股当日开盘15.68元，最高15.85元，最低14.96元，成交额达3773.05万元，换手率为2.15%。近日，公司发布《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案为：以公司总股本160,000,000股为基数，向全体股东每10股派发现金红利3.00元（含税），合计派发现金红利48,000,000.00元（含税）。股权登记日为2026年5月28日，除权除息日为2026年5月29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022455","title":"新光药业（300519）披露2025年年度股东会决议公告，5月18日股价上涨0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022455","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636022455?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:37","pubTimestamp":1779100633,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，新光药业报收于15.93元，较前一交易日上涨0.82%，最新总市值为25.49亿元。该股当日开盘15.8元，最高15.95元，最低15.67元，成交额达3199.97万元，换手率为1.77%。近日，新光药业发布《2025年年度股东会决议公告》。公告显示，公司于2026年5月15日召开2025年年度股东会，会议由董事会召集，董事长王岳钧主持，采用现场与网络投票结合方式召开。出席会议股东共39人，代表股份86,291,100股，占公司有表决权股份总数的53.9319%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800029772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629337084","title":"新光药业(300519)3月31日股东户数1.49万户，较上期减少0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629337084","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629337084?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:20","pubTimestamp":1776763240,"startTime":"0","endTime":"0","summary":"证券之星消息，近日新光药业披露，截至2026年3月31日公司股东户数为1.49万户，较12月31日减少102.0户，减幅为0.68%。在中药行业个股中，新光药业股东户数低于行业平均水平，截至3月31日，中药行业平均股东户数为5.36万户。从股价来看，2025年12月31日至2026年3月31日，新光药业区间涨幅为3.29%，在此期间股东户数减少102.0户，减幅为0.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100039266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740017","title":"新光药业(300519.SZ)发布一季度业绩，归母净利润2636.8万元，增长7.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740017","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628740017?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:02","pubTimestamp":1776686536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新光药业(300519.SZ)发布2026年第一季度报告，该公司营业收入为8846.93万元，同比减少5.13%。归属于上市公司股东的净利润为2636.8万元，同比增长7.44%。归属于上市公司股东的扣除非经常性损益的净利润为2523.85万元，同比增长8.01%。基本每股收益为0.16元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616569513","title":"新光药业（300519）披露持股5%以上股东股份减持计划届满公告，3月2日股价下跌4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616569513","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616569513?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:07","pubTimestamp":1772464034,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，新光药业报收于15.82元，较前一交易日下跌4.12%，最新总市值为25.31亿元。公告显示，持股5%以上股东嵊州市和丰投资股份有限公司减持计划期限届满。在减持计划期间，和丰投资通过集中竞价交易方式减持971,100股，占公司总股本0.6069%；通过大宗交易方式减持210,000股，占公司总股本0.1313%。合计减持1,181,100股，占公司总股本0.7382%。本次减持后，和丰投资持有公司股份23,999,900股，占总股本比例14.9999%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609565598","title":"2月6日新光药业发布公告，股东减持118.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609565598","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609565598?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:01","pubTimestamp":1770379300,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日新光药业发布公告《新光药业:简式权益变动报告书》，其股东嵊州市和丰投资股份有限公司于2025年9月17日至2026年2月5日间合计减持118.11万股，占公司目前总股本的0.7382%，变动期间该股股价下跌2.72%，截止2月5日收盘报16.09元。股东增减持详情见下表：根据新光药业2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600036814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605214548","title":"股市必读：新光药业（300519）1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605214548","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605214548?lang=zh_cn&edition=full","pubTime":"2026-01-21 03:21","pubTimestamp":1768936866,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，新光药业报收于15.91元，下跌0.25%，换手率1.91%，成交量2.18万手，成交额3474.38万元。董秘最新回复投资者： 很多上市公司用自己的产品回馈股东，请问贵公司是否有计划用贵司的主要产品回馈广大股东，同时也可以提高公司的产品知名度董秘： 您好，感谢您对本公司的关注。您的建议很好，我们会向董事会和管理层反馈您的建议。当日关注点来自交易信息汇总：1月20日主力资金净流出213.8万元，散户资金净流入410.42万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100002615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601002172","title":"1月5日新光药业现1笔折价22.24%的大宗交易 合计成交250.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601002172","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601002172?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:36","pubTimestamp":1767605809,"startTime":"0","endTime":"0","summary":"证券之星消息，1月5日新光药业发生大宗交易，交易数据如下：大宗交易成交价格11.92元，相对当日收盘价折价22.24%，成交21万股，成交金额250.32万元，买方营业部为国泰海通证券股份有限公司嵊州高杨路证券营业部，卖方营业部为国泰海通证券股份有限公司嵊州高杨路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2100.0手，折价成交1笔。截至2026年1月5日收盘，新光药业报收于15.33元，上涨2.89%，换手率3.12%，成交量3.56万手，成交额5424.83万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500025318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590595960","title":"新光药业：新药“YHTKL”进入工艺及质量标准研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595960","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590595960?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:31","pubTimestamp":1765441878,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司的创新药研究的怎么样了？新光药业回复：您好，感谢您对本公司的关注。公司定期报告披露的新药“YHTKL”目前已完成处方的基础研究，现已进入工艺及质量标准的研究阶段。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100023799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589850942","title":"新光药业：产品无外销不包括境外地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2589850942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589850942?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:37","pubTimestamp":1764905865,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)12月05日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，看到贵司23、24年财报披露中，有部分营业收入来自“浙江省以外地区”，请问此收入来源地区是否包含境外的国家/地区？如有，是否包含欧盟地区的国家呢？新光药业回复：您好，感谢您对本公司的关注。本公司产品无外销，该部分营业收入不包括境外国家和地区。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514069949","title":"新光药业收盘下跌1.54%，滚动市盈率49.32倍，总市值21.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514069949?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:11","pubTimestamp":1740478305,"startTime":"0","endTime":"0","summary":"2月25日，新光药业今日收盘13.39元，下跌1.54%，滚动市盈率PE达到49.32倍，总市值21.42亿元。从行业市盈率排名来看，公司所处的中药行业市盈率平均38.11倍，行业中值24.67倍，新光药业排名第54位。资金流向方面，2月25日，新光药业主力资金净流出415.71万元，近5日总体呈流出状态，5日共流出797.07万元。最新一期业绩显示，2024年三季报，公司实现营业收入2.16亿元，同比0.05%；净利润3778.24万元，同比-35.63%，销售毛利率35.08%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25181148375901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0132","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501874932","title":"1月8日新光药业发布公告，其股东减持144.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2501874932","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501874932?lang=zh_cn&edition=full","pubTime":"2025-01-08 18:01","pubTimestamp":1736330489,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日新光药业发布公告《新光药业:关于持股5%以上股东减持股份比例达到1%的公告》，其股东嵊州市和丰投资股份有限公司于2024年4月9日至2025年1月6日间合计减持144.6万股，占公司目前总股本的0.9038%，变动期间该股股价上涨10.63%，截止1月6日收盘报13.22元。股东增减持详情见下表：根据新光药业2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010800032168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501216225","title":"新光药业（300519）1月7日主力资金净卖出405.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501216225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501216225?lang=zh_cn&edition=full","pubTime":"2025-01-07 15:27","pubTimestamp":1736234838,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月7日收盘，新光药业报收于12.97元，下跌1.89%，换手率2.94%，成交量3.36万手，成交额4322.4万元。1月7日的资金流向数据方面，主力资金净流出405.8万元，占总成交额9.39%，游资资金净流入54.78万元，占总成交额1.27%，散户资金净流入351.02万元，占总成交额8.12%。新光药业主营业务：主要从事中成药、化学药、保健食品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010700020669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501288452","title":"新光药业1月6日现5笔大宗交易 成交金额1194.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501288452","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501288452?lang=zh_cn&edition=full","pubTime":"2025-01-06 17:00","pubTimestamp":1736154000,"startTime":"0","endTime":"0","summary":" 1月6日，新光药业收涨5.93%，收盘价为13.22元，发生5笔大宗交易，合计成交量119.6万股，成交金额1194.81万元。 第2笔成交价格为9.99元，成交26.50万股，成交金额264.74万元，溢价率为-24.43%，买方营业部为海通证券股份有限公司嵊州高杨路证券营业部，卖方营业部为海通证券股份有限公司嵊州高杨路证券营业部。 进一步统计，近3个月内该股累计发生6笔大宗交易，合计成交金额为1470.81万元。该股近5个交易日累计下跌4.41%，主力资金合计净流入12.08万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-01-06/doc-inecznxv3067159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0132","300519","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501400072","title":"1月6日新光药业现5笔折价24.43%的大宗交易 合计成交1194.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501400072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501400072?lang=zh_cn&edition=full","pubTime":"2025-01-06 16:56","pubTimestamp":1736153811,"startTime":"0","endTime":"0","summary":"证券之星消息，1月6日新光药业发生大宗交易，交易数据如下：近三个月该股共发生6笔大宗交易，合计成交1.45万手，折价成交6笔。该股近期无解禁股上市。截至2025年1月6日收盘，新光药业(300519)报收于13.22元，上涨5.93%，换手率4.43%，成交量5.05万手，成交额6531.59万元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010600023302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493877042","title":"12月24日新光药业现1笔折价20.8%的大宗交易 合计成交276万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493877042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493877042?lang=zh_cn&edition=full","pubTime":"2024-12-24 17:03","pubTimestamp":1735030983,"startTime":"0","endTime":"0","summary":"证券之星消息，12月24日新光药业发生大宗交易，交易数据如下：大宗交易成交价格11.04元，相对当日收盘价折价20.8%，成交25万股，成交金额276万元，买方营业部为中信证券股份有限公司嵊州兴盛街证券营业部，卖方营业部为海通证券股份有限公司嵊州高杨路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2500.0手，折价成交1笔。截至2024年12月24日收盘，新光药业报收于13.94元，上涨1.01%，换手率2.39%，成交量2.73万手，成交额3800.62万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122400030566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300519","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493708651","title":"新光药业12月24日现1笔大宗交易 成交金额276万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493708651","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493708651?lang=zh_cn&edition=full","pubTime":"2024-12-24 17:00","pubTimestamp":1735030800,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第1笔成交价格为11.04元，成交25.00万股，成交金额276.00万元，溢价率为-20.80%，买方营业部为中信证券股份有限公司嵊州兴盛街证券营业部，卖方营业部为海通证券股份有限公司嵊州高杨路证券营业部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为276万元。该股近5个交易日累计下跌3.40%，主力资金合计净流出548.43万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-12-24/doc-ineaqant2919161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0132","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2487537946","title":"新光药业(300519.SZ)股东和丰投资拟减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2487537946","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487537946?lang=zh_cn&edition=full","pubTime":"2024-11-29 19:14","pubTimestamp":1732878880,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新光药业(300519.SZ)公告，公司股东嵊州市和丰投资股份有限公司(简称“和丰投资”)计划于本公告披露之日起15个交易日后的3个月内以集中竞价交易方式和大宗交易方式共计减持其持有的不超过320万股公司股份(即不超过公司总股本的2%)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300519","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2478692002","title":"新光药业（300519）2024年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2478692002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478692002?lang=zh_cn&edition=full","pubTime":"2024-10-25 06:08","pubTimestamp":1729807697,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新光药业发布2024年三季报。根据财报显示，新光药业增收不增利。截至本报告期末，公司营业总收入2.16亿元，同比上升0.05%，归母净利润3778.24万元，同比下降35.63%。按单季度数据看，第三季度营业总收入7000.14万元，同比上升4.36%，第三季度归母净利润1227.47万元，同比下降39.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500005282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2477237042","title":"图解新光药业三季报：第三季度单季净利润同比减39.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477237042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477237042?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:47","pubTimestamp":1729673228,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业2024年三季报显示，公司主营收入2.16亿元，同比上升0.05%；归母净利润3778.24万元，同比下降35.63%；扣非净利润3455.37万元，同比下降37.55%；其中2024年第三季度，公司单季度主营收入7000.14万元，同比上升4.36%；单季度归母净利润1227.47万元，同比下降39.11%；单季度扣非净利润1197.92万元，同比下降38.86%；负债率8.35%，投资收益361.69万元，财务费用-431.27万元，毛利率35.08%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300027175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780641330759,"stockEarnings":[{"period":"1week","weight":-0.0495},{"period":"1month","weight":-0.1702},{"period":"3month","weight":-0.1557},{"period":"6month","weight":-0.1886},{"period":"1year","weight":-0.1119},{"period":"ytd","weight":-0.0916}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0161},{"period":"6month","weight":0.0397},{"period":"1year","weight":0.2019},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江新光药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14930人(较上一季度减少0.68%)","perCapita":"7642股","listingDate":"2016-06-24","address":"浙江省绍兴市嵊州市剡湖街道环城西路25号","registeredCapital":"16000万元","survey":" 浙江新光药业股份有限公司的主营业务是中成药、化学药、保健食品的研发、生产和销售。公司的主要产品是黄芪生脉饮、伸筋丹胶囊、西洋参口服液、黄芪生脉颗粒、增液颗粒、慢支固本颗粒、金胆片、玉屏风口服液、参术儿康糖浆、肾石通颗粒、铁皮枫斗颗粒、复方大青叶合剂、胃炎宁颗粒、生脉饮、复方丹参片、清热解毒口服液。","listedPrice":12.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新光药业,300519,新光药业股票,新光药业股票老虎,新光药业股票老虎国际,新光药业行情,新光药业股票行情,新光药业股价,新光药业股市,新光药业股票价格,新光药业股票交易,新光药业股票购买,新光药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}